NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)

Čájet eará veršuvnnaid (1)

Bibliográfalaš dieđut
Váldodahkkit:	Seed, M, Betteridge, J, Caslake, M, Cooper, J, Humphries, S, Neil, A
Materiálatiipa:	Journal article
Almmustuhtton:	2009

Geahča maid

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
Dahkki: Seed, M, et al.
Almmustuhtton: (2009)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
Dahkki: Neil, A, et al.
Almmustuhtton: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
Dahkki: Neil, H, et al.
Almmustuhtton: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
Dahkki: Neil, H, et al.
Almmustuhtton: (2004)

CURRENT STATIN TREATMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH): RESULTS FROM THE ROYAL COLLEGE OF PHYSICIANS UK NATIONAL AUDIT
Dahkki: Seed, M, et al.
Almmustuhtton: (2011)

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.
Dahkki: Humphries, SE, et al.
Almmustuhtton: (2006)

Elevated lipoprotein(a) levels in Familial Hypercholesterolaemia (FH): prevalence and implications for FH clinical diagnosis
Dahkki: A. David, et al.
Almmustuhtton: (2023-12-01)

The utility of DNA-based testing in patients with familial hypercholesterolaemia in the UK
Dahkki: Humphries, SE, et al.
Almmustuhtton: (2005)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
Dahkki: Neil, A, et al.
Almmustuhtton: (2008)

Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK Biobank
Dahkki: J. Gratton, et al.
Almmustuhtton: (2022-10-01)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
Dahkki: Neil, A, et al.
Almmustuhtton: (2008)

IN APPLICABILITY OF THE CARDIOVASCULAR RISK PREDICTOR "SCORE" TO PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (FH)
Dahkki: Descamps, O, et al.
Almmustuhtton: (2010)

How many individuals with Familial Hypercholesterolaemia (FH) need to be identified to achieve the NHS 2019 Long Term Plan ambition?
Dahkki: S.E. Humphries, et al.
Almmustuhtton: (2023-12-01)

Statins and familial hypercholesterolaemia.
Dahkki: Neil, A, et al.
Almmustuhtton: (2009)

How many homozygous Familial Hypercholesterolaemia (FH) patients are there likely to be in the UK? : The FH phenotype caused by the APOB p.(Arg3527Trp) variant in a South Asian family
Dahkki: I. Tracey, et al.
Almmustuhtton: (2022-10-01)

Identification of FH-causing variants in patients with clinical familial hypercholesterolaemia recruited into the 100,000 genome project: preliminary analysis
Dahkki: A. Rimbert, et al.
Almmustuhtton: (2021-09-01)

A novel combinatorial non-viral vector to treat familial hypercholesterolaemia (FH)
Dahkki: Kerr, A, et al.
Almmustuhtton: (2016)

Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.
Dahkki: Neil, H, et al.
Almmustuhtton: (2003)

Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
Dahkki: Neil, H, et al.
Almmustuhtton: (2005)

Prevalence of familial hypercholesterolaemia (FH)-causing variants and impact on LDL-C concentration in European, South Asian, and African ancestry groups of the UK Biobank
Dahkki: J. Gratton, et al.
Almmustuhtton: (2023-12-01)

More evidence for inflammatory markers in predicting CHD risk
Dahkki: Lyford Joanna, et al.
Almmustuhtton: (2001-03-01)

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
Dahkki: Minhas, R, et al.
Almmustuhtton: (2009)

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation
Dahkki: P Sharma, et al.
Almmustuhtton: (2012-03-01)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Dahkki: Marks, et al.
Almmustuhtton: (2000-01-01)

Does socioeconomic status have an effect on the treatment and outcomes of individuals with familial hypercholesterolaemia (FH)? : a cohort study of individuals with FH in UK primary care
Dahkki: B. Iyen, et al.
Almmustuhtton: (2021-09-01)

Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): a study comparing FH individuals in UK primary care and the UK Simon Broome register linked with secondary care records
Dahkki: B. Iyen, et al.
Almmustuhtton: (2022-10-01)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Dahkki: Marks, D, et al.
Almmustuhtton: (2000)

19. Using a novel combinatorial non-viral vector and small molecules to treat familial hypercholesterolaemia (FH)
Dahkki: Kerr, A, et al.
Almmustuhtton: (2016)

Children and young adults with familial hypercholesterolaemia (FH) have healthier food choices particularly with respect to dietary fat sources compared with non-FH children
Dahkki: Ingunn Molven, et al.
Almmustuhtton: (2013-01-01)

A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.
Dahkki: Marks, D, et al.
Almmustuhtton: (2003)

Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia.
Dahkki: Marks, D, et al.
Almmustuhtton: (2002)

Familial hypercholesterolaemia
Dahkki: D.J. Blom
Almmustuhtton: (2011-01-01)

Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes.
Dahkki: Marks, D, et al.
Almmustuhtton: (2006)

The development of a theory informed behaviour change intervention to improve adherence to dietary and physical activity treatment guidelines in individuals with familial hypercholesterolaemia (FH)
Dahkki: F. J. Kinnear, et al.
Almmustuhtton: (2020-01-01)

Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study.
Dahkki: Neil, H, et al.
Almmustuhtton: (2000)

Cardiovascular Disease Risk Estimation in Mutation Confirmed Familial Hypercholesterolaemia
Dahkki: E. Ofagbor, et al.
Almmustuhtton: (2023-12-01)

Familial hypercholesterolaemia.
Dahkki: Gill, P, et al.
Almmustuhtton: (2012)

Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002.
Dahkki: Neil, H, et al.
Almmustuhtton: (2004)

Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening.
Dahkki: Marks, D, et al.
Almmustuhtton: (2003)

Reduction in cardiovascular disease morbidity of men and women with familial hypercholesterolaemia (FH) associated with availability of high intensity statins: A cohort study using data from the UK Simon Broome Register linked with secondary care records
Dahkki: B. Iyen, et al.
Almmustuhtton: (2021-09-01)